Back to Search
Start Over
Aromatase Inhibition and Capecitabine Combination as 1st or 2nd Line Treatment for Metastatic Breast Cancer - a Retrospective Analysis
- Source :
- Asian Pacific journal of cancer prevention : APJCP. 16(15)
- Publication Year :
- 2015
-
Abstract
- BACKGROUND Preclinical studies have shown that the combination of an aromatase inhibitor (AI) and capecitabine in estrogen receptor (ER)-positive cell lines enhance antitumor efficacy. This retrospective analysis of a group of patients with metastatic breast cancer (MBC) evaluated the efficacy and safety of combined AI with capecitabine. MATERIALS AND METHODS Patients with hormone receptor-positive metastatic breast cancer treated between 1st January 2005 and 31st December 2010 with a combination of capecitabine and AI were evaluated and outcomes were compared with those of women treated with capecitabine in conventional dose or AI as a monotherapy. RESULTS Of 72 patients evaluated, 31 received the combination treatment, 22 AI and 19 capecitabine. The combination was used in 20 patients as first-line and 11 as second-line treatment. Mean age was 46.2 years with a range of 28-72 years. At the time of progression, 97% had a performance status of
- Subjects :
- Oncology
Adult
Diarrhea
Cancer Research
medicine.medical_specialty
Combination therapy
Epidemiology
medicine.drug_class
Anastrozole
Breast Neoplasms
Disease-Free Survival
Capecitabine
Internal medicine
Antineoplastic Combined Chemotherapy Protocols
Nitriles
medicine
Humans
Survival rate
Fatigue
Aged
Retrospective Studies
Aromatase inhibitor
Performance status
business.industry
Aromatase Inhibitors
Letrozole
Public Health, Environmental and Occupational Health
Middle Aged
Triazoles
medicine.disease
Metastatic breast cancer
Surgery
Survival Rate
Receptors, Estrogen
Retreatment
Disease Progression
Female
Hand-Foot Syndrome
business
Receptors, Progesterone
medicine.drug
Follow-Up Studies
Subjects
Details
- ISSN :
- 2476762X
- Volume :
- 16
- Issue :
- 15
- Database :
- OpenAIRE
- Journal :
- Asian Pacific journal of cancer prevention : APJCP
- Accession number :
- edsair.doi.dedup.....cc04c649b1d66bef41675489a1bc8dd0